Loading…
Granules Life Sciences' Hyderabad facility received a 'Voluntary Action Indicated' (VAI) classification from the U.S. Food and Drug Administration (FDA).
This classification followed a comprehensive current Good Manufacturing Practice (cGMP) and Pre-Approval Inspection (PAI) of its oral solid dosage manufacturing operations.
A VAI classification indicates that while some objectionable conditions were observed, they are not severe enough to warrant official regulatory action.
The company is expected to voluntarily address the observations, allowing continued operation of the facility.
After conducting an inspection of a manufacturing facility, the U.S. FDA issues an Establishment Inspection Report (EIR) with one of three classifications, indicating the regulatory status of the facility: 1. **NAI (No Action Indicated):** This signifies that no objectionable conditions were found during the inspection, or any minor issues observed do not warrant regulatory action. 2. **VAI (Voluntary Action Indicated):** This classification means that objectionable conditions were identified, but they are not serious enough to warrant official regulatory action. The company is expected to take voluntary corrective actions to address these observations. 3. **OAI (Official Action Indicated):** This is the most severe classification, indicating that significant objectionable conditions were found that warrant official regulatory action by the FDA. This could lead to import alerts, warning letters, or even facility shutdowns.
Simple Analogy: Imagine a school report card for a factory. 'NAI' is like getting an 'A' – everything is perfect. 'VAI' is like getting a 'B' – there are minor areas for improvement, but you're still doing well overall. 'OAI' is like getting an 'F' – major problems exist that require immediate intervention.
A federal agency of the U.S. Department of Health and Human Services, responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, food supply, cosmetics, and products that emit radiation.
India is a major global supplier of generic drugs. Compliance with stringent international regulatory standards, such as those set by the U.S. FDA, is crucial for Indian pharmaceutical companies to access and maintain their presence in global markets, particularly the lucrative U.S. market.
Current Good Manufacturing Practice (cGMP) standards and regular inspections by regulatory bodies like the FDA are fundamental to ensuring the quality, safety, and efficacy of pharmaceutical products. This directly impacts patient health and trust in medications worldwide.
GS Paper III: Science and Technology – developments and their applications and effects in everyday life. Indian achievements in science and technology. Also relevant for Economy (Industrial Policy, International Trade).
General Awareness: Science & Technology, Organizations.
General Awareness: Economy, Current Affairs, Organizations.
General Science, General Awareness.
Consider the following statements: 1. Biofilms can form on medical implants within human tissues. 2. Biofilms can form on food and food processing surfaces. 3. Biofilms can exhibit antibiotic resistance. Which of the statements given above are correct?
Answer: 1, 2 and 3
Consider the following activities: 1. Spraying pesticides on a crop field 2. Inspecting the craters of active volcanoes 3. Collecting breath samples from spouting whales for DNA analysis At the present level of technology, which of the above activities can be successfully carried out by using drones?
Answer: 1, 2 and 3
Which of the following statements are correct regarding the general difference between plant and animal cells? 1. Plant cells have cellulose cell walls whilst animal cells do not. 2. Plant cells do not have plasma membrane unlike animal cells which do. 3. Mature plant cell has one large vacuole whilst animal cell has many small vacuoles. Select the correct answer using the code given below:
Answer: 1 and 3 only
Regulatory updates and classifications in key industries like pharmaceuticals are frequently tested, especially in UPSC and Banking exams, due to their economic and public health implications.
An FDA inspection classification where objectionable conditions are found but do not warrant official regulatory action, expecting voluntary corrective measures from the company.
Regulations enforced by the FDA to ensure that pharmaceutical products are consistently produced and controlled according to quality standards appropriate for their intended use.
An FDA inspection conducted at a manufacturing facility before a new drug application (NDA) or abbreviated new drug application (ANDA) is approved, to ensure compliance with cGMP and data integrity.
The official report issued by the FDA after completing an inspection of a regulated facility.